Further to the notification made on10 September 2020 ,Benchmark Holdings is pleased to announce that the MRL (Maximum Residue Limit) for its novel sea lice treatment BMK08 has now been ratified under European Law. The MRL confirms the safety of Benchmark's sea lice solution for consumers and represents a significant milestone in the regulatory approval process towards the anticipated commercial launch of BMK08 and CleanTreat inNorway . The commercial launch remains subject to the grant of a Marketing Authorisation inNorway . BMK08 and CleanTreat is a transformational solution addressing the biggest biological challenge in salmon farming. The MRL EU ratification is the culmination of almost a decade of research and development, a rigorous trial programme and substantial capital investment by Benchmark.Trond Williksen , CEO, commented: "The ratification of the MRL is a further stepping stone towards commercialisation following the announcement of our first customer agreements for CleanTreat announced in March. Sea lice continues to be the biggest biological challenge for salmon producers and Benchmark's novel solution addresses this challenge in a sustainable way both in terms of animal welfare and environmental impact."
Click here for more information
© Oslo Bors ASA, source